Trump final Medicare drug pricing rule saves 96% less than initial proposal

The Trump administration issued a final rule to lower Medicare prices for physician-administered drugs, but it applies to only four companies and yields savings 96% below the original proposal. The rule's narrowed scope suggests a significant retreat from earlier ambitions, likely due to industry pressure or legal constraints. This matters as it signals reduced federal intervention in drug pricing, potentially affecting pharmaceutical revenues and patient out-of-pocket costs.